Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen developed Product Technology Rights — Accumulated Amortization ($M) ($M)
Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL)
Latest, Q2 2026
28,450
Period ended Jun 30, 2026
Change on a year earlier
+14.5%
24,846 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Developed Product Technology Rights — Accumulated Amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 28,450 | +14.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 27,604 | +16.3% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 26,754 | +18.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 25,884 | +20.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 24,846 | +22.3% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 23,743 | +23.8% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 22,594 | +25.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 21,472 | +26.8% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 20,320 | +24.6% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 19,184 | +22.4% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 18,049 | +20.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 16,931 | +17.6% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 16,310 | +17.7% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 15,679 | +17.7% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 15,045 | +17.8% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 14,396 | +17.8% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 13,863 | +18.8% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 13,316 | +19.8% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 12,769 | +20.9% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 12,222 | +22.2% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 11,673 | +23.7% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 11,114 | +25.2% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 10,564 | +26.9% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2020 | Sep 30, 2020 | 9,998 | +25.3% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 9,436 | +20.8% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 8,876 | +16.2% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 8,322 | +11.3% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 7,978 | +9.1% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 7,812 | +9.4% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,639 | +9.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 7,479 | +10.1% | Form 10-Q (filed 2019-10-30) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,312 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 7,139 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 6,974 | – | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,796 | +14.3% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | 5,947 | +19.0% | Form 10-K (filed 2018-02-13) ↗ |
| Q4 2015 | Dec 31, 2015 | 4,996 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Developed Product Technology Rights — Accumulated Amortization ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl_devtech_accum
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.